CVRx (CVRX)
Implantable Barostim therapy improves symptoms for eligible heart-failure patients.
Something off on this page? Send us feedback.
Barostim is an implanted baroreflex-activation system for eligible patients with heart failure. CVRx earns from this single commercial platform; U.S. approval is for reduced-ejection-fraction heart failure, while European authorization also covers resistant hypertension.
Built around Barostim, an implantable neuromodulation system that sends electrical pulses to baroreceptors in the carotid-artery wall. In the United States, it is approved to improve symptoms for a defined population with heart failure and reduced ejection fraction.
European authorization covers heart failure and resistant hypertension. Barostim is the sole material commercial focus, and no other products are in development, making the business concentrated rather than portfolio-led.
Adoption and access for the approved U.S. patient population are central dependencies because substantial revenue is expected to come from Barostim. U.S. indications remain distinct from the broader European authorization.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Canaccord Genuity | Target | Target: $10 | Target: $5 |
| Aug 17, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: $13 | Target: $5 |
| Aug 7, 2026 | Lake Street | Downgrade | Target: $12 | Target: $3.50 |
| Aug 7, 2026 | Craig-Hallum | Downgrade | Rating: —Target: $23 | Target: $4 |
| Aug 7, 2026 | Piper Sandler | Downgrade | Target: $16 | Target: $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $64.6M · Total debt $59.4M · Total assets $92.3M · Shareholders' equity $20.0M
- Revenue
- $15.7M
- Operating income
- −$13.0M
- Net income
- −$14.0M
No dividends on record.
| Institutions | 57.54% | 15.33M shares | |
|---|---|---|---|
| 92 holders · as of Jun 30, 2026 | |||
| Insiders | 12.16% | 3.24M shares | |
| 15 holders · as of Aug 24, 2026 | |||
| Strategic holders | 6.42% | 1.71M shares | |
| 1 holder · as of Feb 6, 2025 | |||
| Other | 23.88% | 6.36M shares | |
| remainder | |||
26.64M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Johnson & JohnsonInstitution | 15.11% | 4.02M | as of Jun 30, 2026 |
Nea Management Company, LLCInstitution | 7.34% | 1.95M | as of Jun 30, 2026 |
Vensana Capital I GP, LLCStrategic | 6.42% | 1.71M | filed Feb 6, 2025 |
Chernett JoreyInsider | 5.49% | 1.46M | filed Aug 24, 2026 |
BlackRock, Inc.Institution | 4.67% | 1.25M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Brent Binkowski | officer: CHIEF OPERATING OFFICER | +26,223 | $2.91 |
| Aug 12, 2026 | Brent Binkowski | officer: CHIEF OPERATING OFFICER | −1,309 | $2.55 |
| Mar 2, 2026 | Philip B. Adamson | officer: Chief Medical Officer | −1,262 | $7.90 |
| Mar 2, 2026 | Robert Allen John | officer: Chief Revenue Officer | −3,964 | $7.90 |
| Mar 2, 2026 | Jared Oasheim | officer: CHIEF FINANCIAL OFFICER | −1,744 | $7.90 |
- Abbott
Implantable pulmonary-pressure monitoring for heart-failure management
- Medtronic
CRT devices for selected patients with heart failure
- Boston Scientific
CRT-D systems and HeartLogic heart-failure diagnostics
- Johnson & Johnson
Ventura interatrial-shunt program for HFrEF
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CVRx | $2.81 | −2.77% | $76.7M | — | — | 1.3 | +15.6% |
| Abbott | $103.97 | +0.23% | $179.49B | 33.4 | 17.9 | 3.9 | +13.0% |
| Medtronic | $89.19 | −1.75% | $116.19B | 22.4 | 14.9 | 3.1 | +13.7% |
| Boston Scientific | $44.09 | −1.85% | $66.77B | 18.3 | 13.4 | 3.2 | +7.5% |
| Johnson & Johnson | $266.97 | −0.82% | $648.72B | 31.2 | 22.5 | 6.6 | +6.6% |
| Median | 26.8 | 16.4 | 3.5 | +10.3% |